Drug Type Small molecule drug |
Synonyms Elbasvir/grazoprevir/MK-3682, Elbasvir/grazoprevir/uprifosbuvir + [2] |
Mechanism NS3/NS4A inhibitors(Hepatitis C virus serine protease, NS3/NS4A inhibitors), NS5A inhibitors(Nonstructural protein 5A inhibitors), NS5B polymerase inhibitors(Hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC22H29ClN3O9P |
InChIKeySFPFZQKYPOWCSI-KHFYHRBSSA-N |
CAS Registry1496551-77-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hepatitis C | Phase 2 | - | - |